查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
女性科技与精准医疗在女性健康领域的融合
市场调查报告书
商品编码
1812611

女性科技与精准医疗在女性健康领域的融合

The Convergence of FemTech and Personalised Medicine in Women's Health
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告探讨了女性科技与精准医疗的交汇，并分析了数位健康创新如何重塑女性健康格局。报告探讨了女性科技从以消费者为中心的应用到临床整合解决方案的演变过程、女性健康研究中持续存在的数据缺口，以及产生可靠真实世界证据所面临的课题。

深入了解将数位科技与传统药物治疗结合的策略、全面临床试验设计的重要性，以及製药公司与女性科技新创公司之间合作的关键作用。本报告也探讨了推动创新所需的商业和监管考量，并强调了透过协作和数据驱动的方法改善女性健康状况所带来的更广泛的经济和社会影响。

关键问题解答

  • 1.女性科技如何发展并融入主流医疗保健？
  • 2.造成女性健康资料缺口的因素有哪些？如何解决？
  • 3.数位科技如何在女性健康领域补充传统药物治疗？
  • 4.药厂与女性科技新创公司合作面临哪些课题与机会？
  • 5.药厂和女性科技公司如何为女性健康提供更有力的真实世界证据？
  • 6.女性科技领域的投资与创新面临哪些障碍？
  • 7.临床试验如何更有包容性地纳入女性，包括孕妇和哺乳期妇女？
  • 8.药厂与女性科技公司成功合作需要哪些模式与策略？
  • 9.如何设计数位工具来提高依从性并为女性提供个人化护理？
  • 10.女性科技未来将对女性健康状况以及更广泛的医疗生态系统产生哪些影响？

主要企业

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

参加专家的一部分清单

  • Evinova，数位健康实行领导R&D
  • IBSA UK英国事业部长
  • Theramex CEO
  • UCB，生产适龄期女性计划·全球的·记录磁头

调查手法

本报告是基于独立而简洁的分析，这些分析源自于专有的产业研究以及对产业思想领袖的深入访谈。报告深入分析了製药企业高管需要了解的关键发展和市场趋势，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识缺口。基于这些初步研究，我们创建了基于证据、由专家主导的讨论指南，以确保我们的研究能够解答最重要的问题。此外，我们采用严格的筛选标准，以确保受访者有足够的经验、知识和资格就该主题发表意见。

我们报告的特点

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势，并有效应对复杂的课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访问独家访谈和数据，以及持续的市场监测，确保全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策，并在快速变化的行业中保持竞争力。

简介目录

This report examines the intersection of FemTech and personalised medicine, analysing how digital health innovations are reshaping the landscape of women's health. It explores the evolution of FemTech from consumer-focused applications to clinically integrated solutions, the persistent data gap in women's health research and the challenges of generating robust real-world evidence.

Gain insights into strategies for integrating digital technologies with traditional pharmaceutical treatments, the importance of inclusive clinical trial design and the critical role of partnerships between pharmaceutical companies and FemTech startups. This report also addresses the commercial and regulatory considerations necessary for advancing innovation and highlights the broader economic and societal impact of improving women's health outcomes through collaborative, data-driven approaches.

Key Questions Answered:

  • 1. How is FemTech evolving and being integrated into mainstream healthcare?
  • 2. What factors contribute to the women's health data gap, and how can it be addressed?
  • 3. How can digital technologies complement traditional pharmaceutical treatments in women's health?
  • 4. What are the challenges and opportunities for partnerships between pharmaceutical companies and FemTech startups?
  • 5. How can pharma and FemTech generate more robust real-world evidence for women's health?
  • 6. What are the barriers to investment and innovation in FemTech, and how can they be overcome?
  • 7. How can clinical trials become more inclusive of women, including pregnant and breastfeeding populations?
  • 8. What models and strategies ensure successful collaboration between pharma and FemTech?
  • 9. How can digital tools be designed to improve adherence and personalise care for women?
  • 10. What is the future impact of FemTech on women's health outcomes and the broader healthcare ecosystem?

Key Companies:

  • Clue
  • Evinova
  • IBSA UK
  • Theramex
  • UCB
  • QVin
  • Genentech
  • K'ept Health
  • TherapeuticsMD
  • Agile
  • Eli Health
  • Noom
  • Wisp
  • Incora Health
  • Aura Fertility
  • LiGalli Health
  • Novartis
  • ImageBiopsy Lab
  • Organon
  • Boston Consulting Group

Partial List of Participating Experts:

  • Digital Health Implementation Lead R&D, Evinova
  • General Manager UK operations, IBSA UK
  • CEO, Theramex
  • Global Head of UCB's Women of Childbearing Age Program, UCB

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.